Viktor Rossiev
Samara Regional Clinical Oncology Center(RU)
Publications by Year
Research Areas
Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Eosinophilic Disorders and Syndromes, Systemic Sclerosis and Related Diseases, Legal and Regulatory Analysis
Most-Cited Works
- → Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study(2020)333 cited
- → Effect of FCGR2A and FCGR3A variants on CLL outcome(2010)60 cited
- → Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients(2016)28 cited
- → Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT(2018)19 cited
- → PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia(2014)18 cited
- → Characterization of haematological parameters with bortezomib–melphalan–prednisone versus melphalan–prednisone in newly diagnosed myeloma, with evaluation of long‐term outcomes and risk of thromboembolic events with use of erythropoiesis‐stimulating agents: analysis of the VISTA trial(2011)15 cited
- → Ropeginterferon Alfa‐2b: Efficacy and Safety in Different Age Groups(2020)9 cited
- → Ropeginterferon Alfa-2b versus Standard Therapy for Polycythaemia Vera; a Randomised, Controlled, Phase III Trial(2019)7 cited
- → Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study(2019)4 cited
- → FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.(2009)4 cited